Novartis India Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Novartis India Ltd. on BSE

Search Inside the pdf :

Novartis India Ltd.

14 Apr 2025

850.00

1.23%

Company Update

Novartis India Ltd - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Filing of Certificate in terms of Regulation 74(5) of the SEBI (Depositories & Participants) Regulations, 2018 for the quarter and financial year ended March 31, 2025 received from the RTA dated April 02, 2025.

pdf

Novartis India Ltd.

03 Apr 2025

850.00

1.23%

Company Update

Novartis India Ltd - 500672 - Disclosure Under Regulation 31(4) Of SEBI (Substantial Acquisition Of Shares …

BSE India

We herewith enclose the declaration required to be disclosed under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 received from the promoters of the company.

pdf

Novartis India Ltd.

27 Mar 2025

850.00

1.23%

Company Update

Novartis India Ltd - 500672 - Filing Of Intimation Under Regulation 30 For The Receipt Of …

BSE India

Filing of Intimation under Regulation 30 for the receipt of draft tax assessment order by the Company

pdf

Novartis India Ltd.

27 Mar 2025

850.00

1.23%

Board Meeting

Novartis India Ltd - 500672 - Board Meeting Intimation for The Meeting Of The Board Of …

BSE India

Novartis India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2025 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 09, 2025 to inter alia consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2025 and to recommend dividend on Equity Shares of the Company, if any.

pdf

Novartis India Ltd.

27 Mar 2025

850.00

1.23%

SAST

Novartis India Ltd - 500672 - Closure of Trading Window

BSE India

The meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 09, 2025 to inter alia consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2025 and to recommend dividend on Equity Shares of the Company, if any. The trading window for dealing in shares of the Company by all the Designated Persons and their immediate relatives will be closed with effect from Tuesday, April 01, 2025. The window shall open 48 hours after the said financial results are declared to the Stock Exchange.

pdf

Novartis India Ltd.

04 Mar 2025

850.00

1.23%

Corp. Note

NOVARTIS INDIA LTD. - 500672 - Integrated Filing (Financial)

BSE India

Integrated filing (Financial) for the Quarter and nine months ended December 31 2024.

pdf

Novartis India Ltd.

20 Feb 2025

850.00

1.23%

Company Update

NOVARTIS INDIA LTD. - 500672 - This Is To Inform That The Company Has Received Order …

BSE India

This is to inform that the Company has received order from Assistant Commissioner of CGST and Central Excise and disclosure is given pursuant to Regulation 30 read with Clause 20 Para A of Schedule III

pdf

Novartis India Ltd.

29 Jan 2025

850.00

1.23%

Company Update

NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

This intimation is in relation to the publication of financial results for the Quarter ended as on December 31, 2024, approved by the Board in their meeting held on January 28, 2025, in Newspapers "Financial Express and Navshakti on January 29, 2025.

pdf

Novartis India Ltd.

28 Jan 2025

850.00

1.23%

Result

NOVARTIS INDIA LTD. - 500672 - Filing Of Unaudited Financial Results And Limited Review Report For …

BSE India

We hereby inform that the Board of Directors of the Company at its meeting held today January 28, 2025 have approved the unaudited financials results of the company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee

pdf

Novartis India Ltd.

28 Jan 2025

850.00

1.23%

Board Meeting

NOVARTIS INDIA LTD. - 500672 - Board Meeting Outcome for Filing Of Outcome Of The Meeting …

BSE India

We hereby inform that the Board of Directors ('Board') of the Company at its Meeting held today i.e. January 28, 2025 inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee of the Company.

pdf

Is Novartis India Ltd. worth buying?

62 Votes:

Buy 72.58%

Sell 16.13%

Hold 11.29%